Naji Abumrad

This inventor holds 6 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignees: Mti Biotech, Inc., Metabolic Technologies, Inc., Metaolic Technologies, LLC. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Naji Abumrad. Retrieved from https://idiyas.com/inventor/naji-abumrad

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 19)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 3.4

ph-index = 1

Company Filing History:

Metabolic Technologies, Inc.

patents

1 out of 1

Metaolic Technologies, LLC

Years Active: 2025-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12636269 - Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver (2026-05-26),

2. 12435025 - Triphenylphosphonium-tethered salicylamine derivatives (2025-10-07),

3. 12383515 - Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver (2025-08-12),

4. 12251393 - Compositions containing adenosine triphosphate (ATP) and methods of use (2025-03-18),

5. 12220391 - Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy (2025-02-11),

6. 12208073 - Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma (2025-01-28),

Title: Naji Abumrad: Innovator in Mitochondrial and Liver Health

Introduction

Naji Abumrad is a prominent inventor based in Nashville, TN, known for his significant contributions to the fields of mitochondrial health and liver disease treatment. With a total of five patents to his name, Abumrad has focused on developing innovative solutions aimed at improving health outcomes related to inflammation and oxidative stress.

Latest Patents

Abumrad's latest patents include groundbreaking work on triphenylphosphonium-tethered salicylamine derivatives. These novel salicylamine derivatives are specifically designed to target mitochondria, enhancing their effectiveness while reducing the required dosages for treating conditions caused by inflammation or oxidative stress. Additionally, he has developed compositions and methods for using gamma-ketoaldehyde scavengers to treat, prevent, or improve nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and nonalcoholic steatohepatitis (NASH). These methods and compositions are aimed at addressing liver-related diseases in animals, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Naji Abumrad has worked with notable companies such as Mti Biotech, Inc. and Metabolic Technologies, Inc. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to significant advancements in health-related technologies.

Collaborations

Abumrad has collaborated with professionals like Shawn Baier and John Rathmacher, further enhancing his research and development efforts in the medical field.

Conclusion

Naji Abumrad's innovative work in mitochondrial and liver health exemplifies the impact of dedicated inventors in advancing medical treatments. His patents reflect a commitment to improving health outcomes and addressing critical health challenges.

Profile summary based on public USPTO records.